NCT01728077View on ClinicalTrials.gov

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Epilepsy

Interventions

DRUG

Brivaracetam

Flexible dosing, can up and down-titrate as needed.

Trial Locations (10)

Unknown

103, Little Rock

108, Lexington

109, New York

106, Akron

110, Dallas

102, Salt Lake City

201, Paris

303, Bernau

300, Kehl-Kork

502, Seville

All Listed Sponsors

lead

UCB Pharma SA

INDUSTRY

NCT01728077 - Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy | Biotech Hunter | Biotech Hunter